Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
Cafoli is an early-stage biotechnology company focused on the development of novel small molecule therapeutics for ophthalmic conditions. The company's primary research efforts are directed toward the design of potent and selective carbonic anhydrase inhibitors intended to treat glaucoma and ocular hypertension. By leveraging specialized medicinal chemistry, Cafoli aims to create treatments with improved ocular bioavailability and reduced systemic side effects compared to current standard-of-care therapies. The company is currently in the pre-clinical phase of development, conducting lead optimization and initial safety studies.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Cafoli.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cafoli.